New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study

New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study

Abstract Aim Recently, the neo‐Glasgow prognostic score (GPS), a composite biomarker determined by the C‐reactive protein level and albumin–bilirubin grade, was developed to predict outcomes in hepatocellular carcinoma (HCC) patients who undergo hepatic resection. The present research investigated w...

Full description

Bibliographic Details
Main Authors: Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Kazuya Kariyama, Joji Tani, Masashi Hirooka, Koichi Takaguchi, Masanori Atsukawa, Shinya Fukunishi, Ei Itobayashi, Kunihiko Tsuji, Kazuto Tajiri, Hironori Ochi, Toru Ishikawa, Satoshi Yasuda, Chikara Ogawa, Hidenori Toyoda, Takeshi Hatanaka, Takashi Nishimura, Satoru Kakizaki, Kazuhito Kawata, Noritomo Shimada, Fujimasa Tada, Kazuhiro Nouso, Akemi Tsutsui, Hideko Ohama, Asahiro Morishita, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Hisashi Kosaka, Michitaka Imai, Atsushi Naganuma, Shinichiro Nakamura, Yohei Koizumi, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, the Real‐life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:Cancer Medicine
Subjects:
atezolizumab plus bevacizumab
Glasgow prognostic score
hepatocellular carcinoma
neo‐Glasgow prognostic score
survival
Online Access:https://doi.org/10.1002/cam4.5495

Internet

https://doi.org/10.1002/cam4.5495

Similar Items